PDUFA VIII Would End the Small Business Fee Waiver for Canadian Sponsors

On 14 August 2026, the U.S. Food and Drug Administration published its proposed recommendations for reauthorizing the Prescription Drug User Fee Act, known as PDUFA VIII, covering fiscal years 2028 through 2032 (91 FR 52702). For most readers the word user fee suggests a routine budget notice. This one is not routine. Buried in the proposal are two changes that would directly reduce the financial advantage a Canadian or European small pharmaceutical company enjoys when it files with FDA, plus a new program that makes manufacturing facility readiness an explicit part of the approval conversation.

The comment window is short. Requests to speak at the public meeting close on 2 September 2026, and written comments close on 16 October 2026. This article explains what PDUFA VIII proposes, why it matters to sponsors outside the United States, and what to do now. Every figure below is drawn from the primary Federal Register notice, not from secondary reporting.

Executive Summary

If your company is incorporated in Canada, the United Kingdom, the European Union, or anywhere outside a US State, treat this proposal as a live change to your US filing economics. If you manufacture at a site FDA has not recently inspected, treat the new facility program as a signal that pre-approval inspection readiness now sits on the critical path to approval.

The Four Dates That Matter

What is the deadline? There are four distinct dates in the notice, and they should not be collapsed into one. Missing the speaker request date does not cost you the written comment channel, but the two are weeks apart.

What Is PDUFA VIII?

PDUFA VIII is the eighth reauthorization of the Prescription Drug User Fee Act, the law that lets FDA collect fees from drug and biologic sponsors to fund the review of human drug applications. Why it matters: the current authority expires in September 2027, so Congress must pass new legislation, and the terms are set through a negotiated commitment letter that FDA now puts out for public comment. The choices made in this cycle shape review timelines, meeting rights, and fees for five fiscal years.

The notice satisfies the statutory sequence in section 736B(f)(5) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379h-2(f)(5)), which requires FDA to publish the recommendations, hold a public meeting, and take comment before sending the package to Congress. The full proposed commitment letter is on FDA's user fee program page. PDUFA VII, the current agreement, runs through fiscal year 2027.

Change 1: The Small Business Waiver Would Be Limited to US Companies

What changed? PDUFA VIII proposes to update eligibility for the small business waiver so that it applies only to companies based in the United States, defined in the notice as applicants created or organized under the laws of any State. Why it matters: today a qualifying small business anywhere in the world can seek a waiver of the application fee for its first human drug application. Under the proposal, a Canadian-incorporated small pharma that would otherwise qualify would lose that waiver purely because of where it is organized.

For a first-time filer, the application fee is one of the single largest line items in a submission budget. Losing the waiver does not just add cost, it changes the business case for whether and when a small non-US company files in the United States at all. Companies that have modelled a US launch around a fee waiver should rebuild that model now and decide whether to say so in a comment.

Change 2: A 50 Percent Fee Reduction Tied to a US-Anchored Phase 1 Trial

What changed? Sponsors would receive a 50 percent reduction in the application fee if the application includes clinical data from at least one phase 1 trial anchored in the United States and initiated after 1 October 2027. Why it matters: this is an onshoring incentive. It rewards development programs that run early-phase clinical work in the United States and, by design, offers nothing to a program that ran its phase 1 in Canada, Europe, or elsewhere. For a Canadian sponsor deciding where to site a first-in-human study, the fee reduction is now a real number to weigh against clinical and cost factors.

The reduction attaches to trials initiated after 1 October 2027, so it is forward looking. A program already in phase 1 outside the United States cannot retrofit eligibility. Sponsors planning first-in-human work in 2027 and beyond should factor the incentive, and its geographic condition, into study siting decisions.

Change 3: Orphan Fee Exceptions Would Narrow

What changed? The orphan program fee exemption would be limited to products approved only for orphan indications. A new fee, equal to 50 percent of the full application fee, would apply to the first supplement that seeks approval for a non-orphan indication when the original application used the orphan application fee exception. Why it matters: companies that enter the US market through a rare disease indication and then expand into a broader population have long relied on the orphan exception. This proposal recaptures fees at the point of expansion, so orphan-first commercialization strategies need a refreshed fee forecast.

Change 4: A New CMC Facility Lifecycle Program

What is it? PDUFA VIII proposes a risk-based lifecycle approach to identifying and addressing manufacturing facility deficiencies, called the CMC facility lifecycle program. Why it matters: FDA is openly acknowledging that facility issues are a material cause of approval failure. The program introduces a new option for a single CMC Facility Pre-submission meeting to discuss manufacturing facilities before a facility evaluation and inspection, and adds engagement after the review cycle to discuss inspection findings and the corrective actions that could address them.

FDA also proposes to publish guidance implementing the program and to commission a third-party assessment of its effect on facility-issue-driven complete response letters. In plain terms, chemistry, manufacturing, and controls readiness and pre-approval inspection readiness are moving from a back-office concern to a scheduled, structured conversation with the Agency. Sponsors who treat the pre-approval inspection as something to prepare for in the final weeks are now working against the grain of the program.

Change 5: Meeting Management and the Face-to-Face Request

What changed? PDUFA VIII proposes a new process for sponsors to request that pre-IND, Type C, Type D, and INTERACT meetings be held face-to-face, and if the request is not granted in that format, for FDA to convey a specific rationale for why a written response is sufficient. Why it matters: the formal meeting is where a sponsor and FDA resolve development questions before they become review problems. If you are not already familiar with how these meeting types differ, our guide to FDA meeting types including Type D and INTERACT explains the landscape this proposal would change.

The proposal also folds several PDUFA VII pilots into standard practice. The Model-Informed Drug Development Paired Meeting Program would become Type C-MIDD meetings, working toward removing the quarterly cadence and the cap on requests. The Split Real-Time Application Review pilot and the CMC Development and Readiness Pilot would be discontinued as underutilized or overtaken. Up to 10 Rare Disease Innovation, Science, and Exploration workshops are proposed.

The Money: What Happens to Fee Revenue

The proposed base revenue reflects a reduction of about 56.0 million dollars for administrative efficiencies and an increase of about 7.8 million dollars for net additional positions, a net proposed reduction of 48.3 million dollars to the PDUFA VIII base revenue. For individual sponsors, though, the headline number is less important than the eligibility changes above, which decide who pays full freight and who does not.

What Happens Next in the PDUFA VIII Process

This notice is one step in a defined sequence. FDA negotiated the recommendations with industry, published them for comment, and will hold the public meeting on 16 September 2026. After the comment period closes on 16 October 2026, FDA considers the input, may revise the commitment letter, and transmits the package toward Congress, which must enact the reauthorization before the current authority lapses in September 2027. In other words, the version you are reading is a proposal that can still move before it becomes law.

The practical implication is that the next two months are the window to influence the outcome and to prepare for it. A sponsor that models its own fee exposure now can either advocate for a change through a comment or adjust its filing and trial-siting plans if the proposal holds. The meeting-management changes also interact with FDA's recently finalized formal meetings guidance, so read this proposal together with our guide to FDA formal meeting types to see how the request process and meeting formats would evolve.

One further point is easy to overlook. The proposal ties several changes to fiscal year 2028 and beyond, and the phase 1 fee incentive attaches to trials started after 1 October 2027. Decisions a sponsor makes in 2026 and 2027, about where to incorporate a subsidiary, where to run a first-in-human study, and how to sequence orphan and non-orphan indications, will determine whether these provisions help or hurt when applications are filed later in the PDUFA VIII period.

PDUFA VIII Readiness Checklist

Use this checklist to turn the proposal into concrete actions before the comment window closes.

• Confirm where your company is legally organized and whether you currently rely on the small business waiver.
• Rebuild your US filing fee forecast without the waiver, and separately with and without the 50 percent phase 1 reduction.
• For any first-in-human study planned after 1 October 2027, evaluate whether anchoring a phase 1 trial in the United States is worth the fee reduction.
• If you use an orphan indication as a market entry route, model the fee that would apply at your first non-orphan supplement.
• List every manufacturing site in your filing and note the date of its most recent FDA inspection.
• Schedule a documented facility gap assessment and mock pre-approval inspection for any site not recently inspected.
• Decide whether to request to speak at the 16 September meeting, and calendar the 2 September speaker request deadline.
• Draft and submit a written comment before 16 October 2026 if any provision affects your program. FDA states late comments will not be considered.

Common Mistakes to Avoid

• Treating this as a routine budget notice. The eligibility changes are structural and they favour US-organized sponsors.
• Collapsing the four dates into one. The speaker request date is 2 September, six weeks before the written comment date of 16 October.
• Assuming the phase 1 fee reduction is retroactive. It applies only to trials initiated after 1 October 2027.
• Leaving pre-approval inspection readiness to the final weeks. The new facility program assumes you engage FDA about your site early.
• Relying on secondary reporting for the numbers. Cite the Federal Register notice directly, because several details are easy to paraphrase incorrectly.

Frequently Asked Questions

Can a Canadian company still get the FDA small business fee waiver?

Today, yes, if it meets the size criteria. Under the PDUFA VIII proposal, no. The proposal would limit the waiver to applicants created or organized under the laws of a US State, which would exclude a Canadian-incorporated company. This is a proposal open for comment, not final law, so it can still change.

When is the PDUFA VIII comment deadline?

Written and electronic comments are due by 16 October 2026 at 11:59 p.m. ET through regulations.gov. If you want to speak at the public meeting, the request to speak is due earlier, by 2 September 2026.

What is the CMC Facility Pre-submission meeting?

It is a proposed new single meeting where a sponsor can discuss its manufacturing facilities with FDA before a facility evaluation and inspection, as part of the CMC facility lifecycle program. The aim is to surface and address facility issues earlier, because facility problems are a common cause of approval delay.

How do I qualify for the 50 percent application fee reduction?

Under the proposal, the application would need to include clinical data from at least one phase 1 trial anchored in the United States and initiated after 1 October 2027. A phase 1 trial run entirely outside the United States would not qualify.

Does PDUFA VIII change review timelines?

The core review performance goals for new drug and biologics applications and for manufacturing supplements are described as the same as under PDUFA VII. The most consequential changes in this proposal are to fees, facility engagement, and meeting management, not to the headline review clocks.

Is this final, and can we influence it?

It is a proposed commitment letter, not final law. FDA must hold the public meeting and consider comments before sending the package toward Congress. A well-evidenced comment from an affected sponsor, filed before 16 October 2026, is a legitimate way to influence the outcome.

How MFLRC Can Help

MFLRC works with pharmaceutical and biologic sponsors in Canada, the United States, and Europe on exactly the readiness questions PDUFA VIII sharpens. Our pre-approval inspection readiness assessments and mock inspections map directly onto the new CMC facility lifecycle program, so you walk into an FDA facility conversation already knowing where your gaps are. Start with an inspection readiness self-assessment, then close findings through a structured audit and gap assessment engagement.

On the fee and strategy side, our regulatory affairs, licensing, and import and export team can rebuild your US filing economics under the proposed rules, advise on trial siting for the phase 1 fee reduction, and draft an evidence-based comment for the docket. Because facility findings often trace back to a contract site, our work on supplier and contract manufacturer oversight helps you hold the whole supply chain to the same standard FDA will apply.

Facility findings are now an explicit part of FDA's approval conversation. Book a pre-approval inspection readiness assessment with MFLRC before your next filing.

Conclusion

PDUFA VIII is more than a fee schedule. For sponsors organized outside the United States, it proposes to remove the small business waiver, to reward US-anchored early-phase trials, and to recapture orphan fees at the point of expansion. For every sponsor, it moves manufacturing facility readiness to the centre of the approval conversation. The proposal is open for comment until 16 October 2026, which is a genuine chance to shape the outcome. Read the notice, model your own numbers, and if a provision affects your program, say so on the record.

Sources and References

• FDA, Reauthorization of the Prescription Drug User Fee Act; Public Meeting; Request for Comments, 91 FR 52702 (14 August 2026)
• FDA, Prescription Drug User Fee Amendments program page
• 21 U.S.C. 379h-2, Reauthorization; reporting requirements (section 736B of the FD&C Act)
• RAPS, PDUFA VIII: FDA outlines goals and program enhancements in commitment letter